Evergreening delays access: GBMA

Evergreening strategies delay market entry for generic medicines to the detriment of the Australian community and there is a lack of evidence to support extending market exclusivity for pharmaceuticals, according to the Productivity Commission’s draft report into Australia’s intellectual property arrangements. The report's release has been welcomed by the Generic and Biosimilar Medicines Association. “The